Antibody Engineering & Design 2010. 24-25 February 2010, Frankfurt, Germany.
The Antibody Engineering & Design 2010 conference, held in Frankfurt, included topics covering new developments in the field of therapeutic antibodies. This conference report highlights selected presentations on 'fit for purpose' biologics, improving the pharmaceutical properties of antibodies, the selection of antibody fragments for therapeutic use, challenges in biopharmaceutical manufacturing, developing dual-targeting antibodies, epitope mapping, and the development of two novel mAbs. Investigational drugs discussed include 1D4.1-ABT325 (Abbott Laboratories), Sym-004 (Symphogen A/S) and CNTO-607 (Johnson & Johnson).
Beck
Alain
A
Centre d'Immunologie Pierre Fabre, 5 Avenue Napoleon III, 74160 Saint-Julien-en-Genevois, France. alain.beck@pierre-fabre.com
D000818:Animals; D000906:Antibodies / Q000494:pharmacology* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D016503:Drug Delivery Systems; D015195:Drug Design; D004345:Drug Industry / Q000379:methods; D015507:Drugs, Investigational / Q000494:pharmacology* / Q000627:therapeutic use; D018604:Epitope Mapping / Q000379:methods; D006801:Humans; D007128:Immunoglobulin Fragments / Q000494:pharmacology / Q000627:therapeutic use; D015202:Protein Engineering / Q000379:methods*
D000906:Antibodies; D000911:Antibodies, Monoclonal; D015507:Drugs, Investigational; D007128:Immunoglobulin Fragments